Achilles Therapeutics plc
ACHL · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $5 | $4 | $3 | $1 |
| Gross Profit | -$5 | -$4 | -$3 | -$1 |
| % Margin | – | – | – | – |
| R&D Expenses | $68 | $57 | $42 | $23 |
| G&A Expenses | $17 | $21 | $22 | $11 |
| SG&A Expenses | $12 | $21 | $22 | $11 |
| Sales & Mktg Exp. | -$5 | $0 | $0 | $0 |
| Other Operating Expenses | -$9 | $7 | $3 | $1 |
| Operating Expenses | $75 | $78 | $64 | $34 |
| Operating Income | -$75 | -$78 | -$64 | -$34 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $6 | $7 | $3 | $1 |
| Pre-Tax Income | -$69 | -$71 | -$61 | -$33 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$70 | -$71 | -$61 | -$33 |
| % Margin | – | – | – | – |
| EPS | -1.74 | -1.82 | -2.13 | -0.82 |
| % Growth | 4.4% | 14.6% | -159.8% | – |
| EPS Diluted | -1.74 | -1.82 | -2.13 | -0.82 |
| Weighted Avg Shares Out | 40 | 39 | 29 | 41 |
| Weighted Avg Shares Out Dil | 40 | 39 | 29 | 41 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $5 | $4 | $3 | $1 |
| EBITDA | -$70 | -$67 | -$61 | -$33 |
| % Margin | – | – | – | – |